Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast‐feeding
- 28 November 2005
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 61 (2) , 155-163
- https://doi.org/10.1111/j.1365-2125.2005.02538.x
Abstract
Aims: To compare the disposition of fluoxetine and norfluoxetine enanantiomers in the mother, foetus and infant.Methods: Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery. The subset of these women who were breastfeeding, plus additional subjects recruited in the postpartum period, were studied further, and maternal and infant blood, and breast milk was sampled between 6 days and 11 months (n = 23). Drug and metabolite concentrations were measured using gas chromatography/mass spectrometry or liquid chromatography, tandem mass spectrometry.Results: There was a high correlation between maternal and foetal (cord blood) fluoxetine and norfluoxetine enantiomers (r2−0.9), the mean foetal/maternal ratios (95% confidence intervals) being 0.91 (0.61, 1.02) and 1.04 (0.93, 1.05), for fluoxetine and norfluoxetine, respectively. In 2 day old infants exposed to the drugin utero, the fluoxetine and norfluoxetine plasma concentrations were the same as in cord blood at delivery. Over the next 2 months, the plasma concentrations in the infants fell progressively. Stereoselective disposition of both the drug and metabolite in the mother, foetus, infant and breast milk was observed. The S : R ratios in the foetus and newborn (∼3) were significantly higher than in the serum (∼2) or breast milk (∼1.9) of the mothers, resulting in greater exposure of the foetus and infants to the biologically active enantiomers, particularly S‐norfluoxetine.Conclusions: Foetal and infant exposure to fluoxetine and norfluoxetine is enhanced by their stereoselective disposition in the mother, foetus, breast milk and infant. Increased exposure may also result from decreased metabolism of the drug in the foetus and neonate.Keywords
This publication has 36 references indexed in Scilit:
- Pain Reactivity in 2-Month-Old Infants After Prenatal and Postnatal Selective Serotonin Reuptake Inhibitor Medication ExposurePediatrics, 2005
- Health, Sociodemographic Data, and Pregnancy Outcome in Women With Antepartum Depressive SymptomsObstetrics & Gynecology, 2004
- JUD COON: 35 YEARS OF P450 RESEARCH, A SYNOPSIS OF P450 HISTORYDrug Metabolism and Disposition, 2004
- Placental Passage of Antidepressant MedicationsAmerican Journal of Psychiatry, 2003
- The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative EnzymesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Distribution and excretion of fluoxetine and norfluoxetine in human milkBritish Journal of Clinical Pharmacology, 1999
- Report from the Second European Stroke Summer School, Heidelberg, GermanyCerebrovascular Diseases, 1999
- A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonateInternational Journal of Neuropsychopharmacology, 1999
- Excretion of Fluoxetine and Its Metabolite, Norfluoxetine, in Human Breast MilkThe Journal of Clinical Pharmacology, 1996
- Excretion of Psychoactive Drugs into Breast MilkClinical Pharmacokinetics, 1994